DK0652943T3 - Hæmatopoietiske, fremmende celler og anvendelse deraf - Google Patents

Hæmatopoietiske, fremmende celler og anvendelse deraf

Info

Publication number
DK0652943T3
DK0652943T3 DK93918173T DK93918173T DK0652943T3 DK 0652943 T3 DK0652943 T3 DK 0652943T3 DK 93918173 T DK93918173 T DK 93918173T DK 93918173 T DK93918173 T DK 93918173T DK 0652943 T3 DK0652943 T3 DK 0652943T3
Authority
DK
Denmark
Prior art keywords
bone marrow
cells
hematopoietic
marrow cells
engraftment
Prior art date
Application number
DK93918173T
Other languages
English (en)
Inventor
Suzanne T Ildstad
Richard L Simmons
Camillo Ricordi
Sherry M Wren
Christina Kaufman
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Application granted granted Critical
Publication of DK0652943T3 publication Critical patent/DK0652943T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK93918173T 1992-07-10 1993-07-09 Hæmatopoietiske, fremmende celler og anvendelse deraf DK0652943T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US91198992A 1992-07-10 1992-07-10
US99654492A 1992-12-24 1992-12-24
US6931593A 1993-05-28 1993-05-28
PCT/US1993/006506 WO1994001534A1 (en) 1992-07-10 1993-07-09 Hematopoietic facilitatory cells and their uses

Publications (1)

Publication Number Publication Date
DK0652943T3 true DK0652943T3 (da) 2008-11-03

Family

ID=27371514

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93918173T DK0652943T3 (da) 1992-07-10 1993-07-09 Hæmatopoietiske, fremmende celler og anvendelse deraf

Country Status (12)

Country Link
EP (1) EP0652943B1 (da)
JP (1) JP3917652B2 (da)
AT (1) ATE399854T1 (da)
AU (1) AU688734B2 (da)
CA (1) CA2139877C (da)
DE (1) DE69334227D1 (da)
DK (1) DK0652943T3 (da)
ES (1) ES2309985T3 (da)
NZ (2) NZ255039A (da)
PT (1) PT652943E (da)
SG (1) SG55145A1 (da)
WO (1) WO1994001534A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE276277T1 (de) * 1994-01-05 2004-10-15 Univ Pittsburgh Monoklonale antikörper gegen antigene, die durch hämatopoietische helferzellen exprimiert werden
WO1996015227A1 (en) * 1994-11-14 1996-05-23 Novartis Ag Methods of inducing cell death of primitive hematopoietic cells and compositions for induction thereof
CA2303008A1 (en) * 1997-09-10 1999-03-18 Emory University Methods for inhibiting rejection of transplanted tissues by bone grafting
US8252587B2 (en) 2004-10-25 2012-08-28 Celerant Therapeutics, Inc. Methods of expanding myeloid cell populations and uses thereof
WO2007095594A2 (en) * 2006-02-14 2007-08-23 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
US8632768B2 (en) * 2008-05-30 2014-01-21 University Of Louisville Research Foundation, Inc. Human facilitating cells
JP6401445B2 (ja) * 2013-10-10 2018-10-10 国立大学法人 東京大学 造血幹細胞移植用の組合せ細胞製剤および生着促進剤並びにこれらの製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
JPH06510672A (ja) * 1991-11-05 1994-12-01 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー サプレッサーおよび前駆細胞

Also Published As

Publication number Publication date
ES2309985T3 (es) 2008-12-16
CA2139877C (en) 2006-09-19
WO1994001534A1 (en) 1994-01-20
AU688734B2 (en) 1998-03-19
ATE399854T1 (de) 2008-07-15
NZ255039A (en) 1997-03-24
EP0652943B1 (en) 2008-07-02
CA2139877A1 (en) 1994-01-20
AU4771793A (en) 1994-01-31
SG55145A1 (en) 1998-12-21
JPH08500009A (ja) 1996-01-09
DE69334227D1 (de) 2008-08-14
PT652943E (pt) 2008-10-09
HK1010739A1 (en) 1999-06-25
EP0652943A4 (en) 1996-02-07
JP3917652B2 (ja) 2007-05-23
EP0652943A1 (en) 1995-05-17
NZ299935A (en) 2000-07-28

Similar Documents

Publication Publication Date Title
Luria et al. Bone formation in organ cultures of bone marrow
Hajdu et al. Tendosynovial sarcoma. A clinicopathological study of 136 cases
Nade et al. Decalcified bone as a substrate for osteogenesis. An appraisal of the interrelation of bone and marrow in combined grafts
US7347999B2 (en) Methods of treatment of hematopoietic disorders
Lawler et al. Cytogenetic studies on recipients of allogeneic bone marrow using the sex chromosomes as markers of cellular origin
EP2033514A3 (en) Carbon Monoxide Improves Outcomes in Cell and Organ Transplants and Suppresses Apoptosis
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
JP2003277293A5 (da)
NZ335531A (en) Composition and methods of producing human cartilage tissue
HUP9903072A2 (hu) 5,7-Dihidroxi-kromán-4-on-származékok az immunválasz elnyomására
DE60129007D1 (de) Vermehrung des weich- sowie des knochengewebes anhand von aus muskeln stammenden vorläuferzellen, sowie damit verbundene zusammensetzungen und behandlungsformen
IL153570A0 (en) Purging of cells using viruses
CA2213322A1 (en) Thiols to promote hematopoietic progenitor cell growth
CA2272130A1 (en) Methods for preventing graft rejection in transplantation and for producing a universal gene therapy host cell using lymphocyte activation (lag-3)
ATE300310T1 (de) Verfahren zur steigerung von hematopoietischen zellen
WO2002024244A3 (en) Method of preparing and processing transplant tissue
SG55145A1 (en) Hematopoietic facilitatory cells and their uses
WO2002040640A3 (en) Methods of using cd8+/tcr- facilitating cells (fc) for the engraftment of purified hematopoietic stem cells (hsc)
WO1999061589A3 (en) Expansion of hematopoietic stem cells transduced with mdr-1 and methods of use thereof
Vigneau et al. Stem cells and kidney injury
Anwar et al. Therapeutic potential of umbilical cord stem cells for liver regeneration
CA2384418A1 (en) Use of cytokines, cells, and mitogens to inhibit graft versus host disease
Mozziconacci et al. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case
Vossen Bone marrow transplantation in the treatment of severe immunodeficiencies: possibilities and problems
Ioachim et al. Antigenic deletion and malignant enhancement induced in lymphoma cells by passage through X-irradiated hosts